Zevra Therapeutics’ MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease
Zevra Therapeutics Inc. has announced U.S. Food and Drug Administration (FDA) approval of MIPLYFFA (arimoclomol), a capsule-based treatment for Niemann-Pick disease type C (NPC), a ... Read More
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More
Terns Pharmaceuticals faces market pressure following stock offering announcement
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and obesity, has seen a significant decline in ... Read More